Birch bark extract and its preparations containing betulin
By preparing solid birch bark extract containing betulin and triterpenes, and formulating it into oil gels, emulsions, and foams, the problem of skin deterioration caused by the application of existing birch bark extracts has been solved, achieving safe and effective wound healing and treatment of bullous epidermolysis.
Patent Information
- Application Number
- CN202611300599.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-01-04
- Filing Date
- 2019-01-04
- Publication Date
- 2026-11-10
AI Technical Summary
Existing birch bark extract oil gels and lotions may worsen skin conditions during application, especially epidermolysis bullosa.
A solid birch bark extract containing at least 70% betulinol and triterpenoids is provided, which is prepared into oleogels, emulsions and foams that can be dispersed in nonpolar liquids through specific extraction, crystallization and drying processes, ensuring improved rheological properties in clinical applications and avoiding the adverse effects of direct skin contact.
It achieves the avoidance of skin condition deterioration in the treatment of wounds and epidermolysis bullosa, provides clinically beneficial wound healing effects, and the oleogels, emulsions and foams have suitable viscosity and consistency for sterile wound dressings.
Smart Images

Figure CN123059094A_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese Patent Application No. 201980005700.0 (Application Date: January 4, 2019, Invention Title: Birch Bark Extract Containing Betulin and Preparations Thereof).
[0002] Cross-reference to related applications
[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 613,646, filed January 4, 2018, the entire contents of which are incorporated herein by reference in their entirety for all purposes. Technical Field
[0004] This disclosure relates to pharmaceutical preparations derived from extracts derived from birch bark. Background Technology
[0005] Triterpenes found in birch bark extracts are known to have wound-healing properties. Methods for extracting these triterpenes from birch bark are reported in U.S. Patent No. 7,482,383. These methods provide solid birch bark extracts that can be used in pharmaceutical formulations. For example, emulsions containing such extracts are described in U.S. Patent No. 7,482,383, and oleogels containing such extracts are described in U.S. Patent Nos. 9,352,041, 8,828,444, and 8,536,380.
[0006] For clinical application in wound healing, the oil gel must be applied to the area of skin requiring treatment by touch. Touch application is detrimental to the treatment of certain skin conditions (e.g., epidermolysis bullosa) because the simple act of applying the oil gel may worsen the skin condition.
[0007] Therefore, there is a need for wound healing preparations containing solid birch bark extract that can be applied to the skin without worsening the patient's condition.
[0008] This disclosure provides clinically advantageous wound healing formulations (including oleogels, emulsions, and foams) with improved rheological properties, overcoming the disadvantages of known emulsions and oleogels containing solid birch bark. Summary of the Invention
[0009] This disclosure provides a solid birch bark extract containing at least about 70% by weight betulin and one or more triterpenes selected from the group consisting of betulinic acid, oleanolic acid, coca glycol, and lupeol. The solid birch bark extract described herein can be formulated in an oleogel having clinically advantageous rheological properties.
[0010] This disclosure also provides a method for preparing a solid birch bark extract that can be dispersed in a nonpolar solvent to provide a clinically advantageous oleogel, the method comprising the steps of: (a) contacting birch bark with a suitable solvent to form an extract comprising betulin and at least one triterpene; (b) separating the birch bark from the extract; (c) cooling the extract to allow a portion of the betulin and triterpene to crystallize from the solution; (d) separating the crystallized betulin and triterpene; and (e) drying the separated crystallized betulin and triterpene to form a solid birch bark extract. This disclosure also provides a solid birch bark extract prepared according to these methods.
[0011] This disclosure provides a clinically advantageous oleogel comprising about 1% to 20% by weight particles of a solid birch bark extract dispersed in about 80% to about 99% by weight of one or more nonpolar liquids, the solid birch bark extract being dispersed in a suitable nonpolar liquid to form the oleogel. A sterile wound dressing is also provided, comprising a pad and a therapeutically effective amount of the oleogel.
[0012] This disclosure provides an emulsion comprising the oleogel of the present invention and also provides a foam comprising the emulsion of the present disclosure.
[0013] This disclosure also provides a method for treating a patient's wound by topically applying an effective amount of the disclosed oleogel, emulsion, or foam to at least a portion of the wound.
[0014] This disclosure also provides a method for treating bullous epidermolysis in patients in need, the method comprising applying an effective amount of the oil gel, emulsion or foam of this disclosure topically to the area of bullous epidermolysis in the patient.
[0015] This disclosure provides solid birch bark extract, oleogel, sterile wound dressing, preparation method, emulsion, foam, pressurized container, method for treating wounds, and method for treating epidermolysis bullosa according to embodiments numbered below:
[0016] 1. A solid birch bark extract comprising at least about 70% by weight betulin and one or more triterpenes selected from the group consisting of betulinic acid, oleanolic acid, coca glycol and lupeol.
[0017] 2. The solid birch bark extract as described in embodiment 1, wherein, when chromatographically analyzed according to the following HPLC method, the solid birch bark extract has the same properties as... Figure 1 Essentially the same HPLC chromatograms:
[0018]
[0019] Column: C18, 2.6 μm, 150 x 2.1 mm; Detector: 210 nm and 320 nm;
[0020] The relative retention time of betulinic acid is about 0.75-0.90, the relative retention time of oleanolic acid is about 0.84-0.97, the relative retention time of betulinol is 1.00, the relative retention time of coca diol is about 1.25-1.40, and the relative retention time of lupeol is about 3.50-4.15.
[0021] 3. The solid birch bark extract as described in embodiment 1 or 2 is prepared by a process including the following steps:
[0022] (a) Contacting birch bark with a pharmaceutically acceptable solvent to form an extract containing betulin and one or more triterpenes;
[0023] (b) Separating the birch bark from the extract;
[0024] (c) Cool the extract, thereby crystallizing betulin and a portion of one or more triterpenes from the cooled extract;
[0025] (d) Separate the crystallized betulinol and one or more triterpenes from the cooled extract;
[0026] (e) The isolated crystalline betulinol and one or more triterpenes are dried to provide the solid birch bark extract;
[0027] In step (e), approximately 1% to approximately 20% by weight of the dried solid birch bark extract dispersed in refined sunflower oil after drying forms an oil gel.
[0028] 4. The solid birch bark extract as described in embodiment 3, wherein one or more of steps (a), (c), and (e) are performed under the following conditions:
[0029] (i) The contact described in step (a) is performed at a temperature of about 60°C to about 130°C;
[0030] (ii) Perform the cooling described in step (c) at a temperature of about -20°C to about 35°C;
[0031] (iii) The drying described in step (e) is carried out at a pressure of less than about 70 mbar and a temperature of about 75°C to about 95°C.
[0032] 5. The solid birch bark extract as described in embodiment 3, wherein two or more of steps (a), (c), and (e) are performed under the following conditions:
[0033] (i) The contact described in step (a) is performed at a temperature of about 60°C to about 130°C;
[0034] (ii) Perform the cooling described in step (c) at a temperature of about -20°C to about 35°C;
[0035] (iii) The drying described in step (e) is carried out at a pressure of less than about 70 mbar and a temperature of about 75°C to about 95°C.
[0036] 6. The solid birch bark extract as described in embodiment 3, wherein steps (a), (c), and (e) are performed under the following conditions:
[0037] (i) The contact described in step (a) is performed at a temperature of about 60°C to about 130°C;
[0038] (ii) Perform the cooling described in step (c) at a temperature of about -20°C to about 35°C;
[0039] (iii) The drying described in step (e) is carried out at a pressure of less than about 70 mbar and a temperature of about 75°C to about 95°C.
[0040] 7. A solid birch bark extract as described in any one of embodiments 3-6, wherein the pharmaceutically acceptable solvent is a hydrocarbon or an alcohol or a combination thereof.
[0041] 8. A solid birch bark extract as described in any one of embodiments 3-7, wherein the pharmaceutically acceptable solvent is a hydrocarbon selected from the group consisting of n-pentane, n-hexane, or n-heptane.
[0042] 9. The solid birch bark extract as described in embodiment 8, wherein the pharmaceutically acceptable solvent is n-heptane, and the contact is carried out at a temperature of about 60°C to about 130°C for about 8-12 minutes.
[0043] 10. A solid birch bark extract as described in any one of embodiments 3-9, wherein the cooled extract in step (c) is at least about 2 times supersaturated.
[0044] 11. The solid birch bark extract as described in embodiment 10, wherein the cooled extract is supersaturated by about 5 times.
[0045] 12. The solid birch bark extract as described in any one of embodiments 3-11, wherein the amount of residual extraction solvent does not exceed about 0.5% by weight.
[0046] 13. An olegel comprising about 1% to about 20% by weight of a solid birch bark extract as described in any one of embodiments 1-12, the particles having an average particle size of less than about 50 μm, dispersed in about 80% to about 99% by weight of one or more nonpolar liquids.
[0047] 14. The oleogel as described in embodiment 13, wherein the dispersed solid birch bark extract particles are the only oleogel forming agent in the oleogel.
[0048] 15. The oleogel as described in embodiment 13 or 14, comprising about 10% by weight of particles of the solid birch bark extract.
[0049] 16. The oleogel of any one of embodiments 13 to 15, wherein the nonpolar liquid comprises at least one triglyceride.
[0050] 17. The oleogel of any one of embodiments 13 to 16, wherein the nonpolar liquid comprises at least one C7 or higher hydrocarbon.
[0051] 18. The oleogel as described in embodiment 16, wherein the nonpolar liquid comprises one or more vegetable oils.
[0052] 19. The oleogel as described in embodiment 18, wherein the nonpolar liquid comprises sunflower oil.
[0053] 20. The oleogel as described in any one of embodiments 13-19, wherein the peroxide value of the nonpolar liquid is less than about 10.
[0054] 21. The oleogel as described in embodiment 20, wherein the peroxide value does not exceed about 3.
[0055] 22. The oleogel as described in any one of embodiments 13-21, wherein the oleogel is substantially free of solid birch bark extract particles with a size greater than about 50 μm.
[0056] 23. The oleogel as described in any one of embodiments 13-22, wherein the oleogel is sterile.
[0057] 24. The oleogel as described in embodiment 23, wherein the oleogel is sterilized with ionizing radiation at a dose of less than about 20 kGy.
[0058] 25. The oleogel as described in embodiment 24, wherein the oleogel is sterilized with ionizing radiation ranging from about 11 kGy to about 20 kGy.
[0059] 26. The oleogel as described in any one of embodiments 13-25, wherein after centrifugation at 2750 g for 30 minutes at 25°C, less than about 10% of the nonpolar liquid separates from the oleogel.
[0060] 27. The oleogel as described in any one of embodiments 13-26, wherein the viscosity of the oleogel at 200 s ranges from about 0.5 Pa·s to about 4.0 Pa·s, and the thixotropic value of the oleogel ranges from about 200 Pa·s to about 1200 Pa·s, as measured using a cone-plate viscometer according to the rotational viscometer method described in European Pharmacopoeia 2.2.10.
[0061] 28. An oleogel as described in any one of embodiments 13-27, wherein the consistency of the oleogel ranges from about 300 mN to 3000 mN, as measured accordingly using a texture analyzer.
[0062] 29. The oleogel as described in any one of embodiments 13-28 further comprises a disinfectant.
[0063] 30. The oleogel as described in embodiment 29, wherein the disinfectant is selected from the group consisting of ethanol, n-propanol and isopropanol.
[0064] 31. The oleogel as described in any one of embodiments 13-28 further comprises a lipophilic antibiotic.
[0065] 32. A sterile wound dressing, said sterile wound dressing comprising:
[0066] (a) pad, and
[0067] (b) A therapeutic layer comprising an oleogel as described in any one of embodiments 13-31 disposed on at least one surface of the pad.
[0068] 33. The sterile wound dressing as described in embodiment 32, wherein the pad is an absorbent pad.
[0069] 34. A method for preparing a solid birch bark extract as described in embodiment 1 or 2, the method comprising:
[0070] (a) Contacting birch bark with a pharmaceutically acceptable solvent to form an extract containing betulin and one or more triterpenes;
[0071] (b) Separating the birch bark from the extract;
[0072] (c) Cool the extract, thereby crystallizing betulin and a portion of one or more triterpenes from the cooled extract;
[0073] (d) Separate the crystallized betulinol and one or more triterpenes from the cooled extract;
[0074] (e) The isolated crystalline betulinol and one or more triterpenes are dried to provide the solid birch bark extract;
[0075] In step (e), approximately 1% to approximately 20% by weight of the dried solid birch bark extract dispersed in refined sunflower oil after drying forms an oil gel.
[0076] 35. The method of embodiment 34, wherein one or more of steps (a), (c), and (e) are performed under the following conditions:
[0077] (i) The contact described in step (a) is performed at a temperature of about 60°C to about 130°C;
[0078] (ii) Perform the cooling described in step (c) at a temperature of about -20°C to about 35°C;
[0079] (iii) The drying described in step (e) is carried out at a pressure of less than about 70 mbar and a temperature of about 75°C to about 95°C.
[0080] 36. The method of embodiment 34, wherein two or more of steps (a), (c) and (e) are performed under the following conditions:
[0081] (i) The contact described in step (a) is performed at a temperature of about 60°C to about 130°C;
[0082] (ii) Perform the cooling described in step (c) at a temperature of about -20°C to about 35°C;
[0083] (iii) The drying described in step (e) is carried out at a pressure of less than about 70 mbar and a temperature of about 75°C to about 95°C.
[0084] 37. The method as described in embodiment 34, wherein steps (a), (c), and (e) are performed under the following conditions:
[0085] (i) The contact described in step (a) is performed at a temperature of about 60°C to about 130°C;
[0086] (ii) Perform the cooling described in step (c) at a temperature of about -20°C to about 35°C;
[0087] (iii) The drying described in step (e) is carried out at a pressure of less than about 70 mbar and a temperature of about 75°C to about 95°C.
[0088] 38. The method of any one of embodiments 34-37, wherein the pharmaceutically acceptable solvent is a hydrocarbon selected from the group consisting of n-pentane, n-hexane or n-heptane.
[0089] 39. The method of any one of embodiments 34-38, wherein the pharmaceutically acceptable solvent is n-heptane, and the contact is carried out at a temperature of about 115°C to about 130°C for about 8-12 minutes.
[0090] 40. The method of any one of embodiments 34-39, wherein the cooled extract in step (c) is supersaturated by at least about 2 times.
[0091] 41. The method of embodiment 40, wherein the cooled extract is supersaturated by about 5 times.
[0092] 42. The method of any one of embodiments 34-41, wherein the amount of residual extraction solvent does not exceed about 0.5 by weight.
[0093] 43. An emulsion comprising a solid birch bark extract as described in any one of embodiments 1-12.
[0094] 44. An emulsion comprising an oleogel as described in any one of embodiments 13-31.
[0095] 45. The emulsion as described in embodiment 43 or 44, wherein the emulsion is a water-in-oil emulsion.
[0096] 46. The emulsion as described in embodiment 45 is substantially free of emulsifiers.
[0097] 47. The emulsion as described in any one of embodiments 43-46 is substantially composed of the solid birch bark extract or oleogel, oil, and water.
[0098] 48. The emulsion as described in any one of embodiments 44-46, comprising the oleogel, oil and water.
[0099] 49. The emulsion as described in any one of embodiments 43-46 further comprises a disinfectant.
[0100] 50. The emulsion as described in embodiment 49, wherein the disinfectant is selected from the group consisting of ethanol, n-propanol and isopropanol.
[0101] 51. The emulsion according to any one of embodiments 43-46 further comprises a lipophilic antibiotic.
[0102] 52. A foam comprising an emulsion as described in any one of embodiments 43-51.
[0103] 53. The foam as described in embodiment 52 further comprises a disinfectant.
[0104] 54. The foam as described in embodiment 53, wherein the disinfectant is selected from the group consisting of ethanol, n-propanol and isopropanol.
[0105] 55. The foam as described in embodiment 52 further contains a lipophilic antibiotic.
[0106] 56. The foam as described in any one of embodiments 52-55, wherein the interfacial surface tension of the emulsion is greater than about 4 mN / m.
[0107] 57. The foam as described in any one of embodiments 52-56, wherein the foam index is greater than about 2.
[0108] 58. The foam as described in embodiment 52, wherein the oleogel is composed of about 5% to about 10% by weight of solid birch bark extract, and the emulsion is a water-in-oil emulsion composed of the oleogel and about 20% to about 30% by weight of water.
[0109] 59. The foam as described in embodiment 58, wherein the oleogel consists of about 7% by weight of solid birch bark extract and the amount of water in the emulsion is about 25% by weight.
[0110] 60. The foam according to any one of embodiments 52-56 further comprises an emulsifier selected from the group consisting of phosphatidylcholine, polyglycerol-3-methylglucose distearate, and combinations thereof.
[0111] 61. A pressurized container filled with a mixture comprising an emulsion as described in any one of embodiments 43-51 and a pharmaceutically acceptable propellant, wherein the emulsion foams when at least a portion of the mixture is poured out of the container.
[0112] 62. A method of treating a patient's wound, the method comprising applying a topical oleogel as described in any one of embodiments 13-31 to at least a portion of the wound.
[0113] 63. The oleogel as described in any one of embodiments 13-31, for use in a method of treating a wound.
[0114] 64. The method or oleogel for use as described in embodiment 63, wherein the wound is selected from the group consisting of: burns, surgical skin damage, superficial injuries, chronic wounds, pressure sores, diabetic foot ulcers, chronic venous ulcers, arterial insufficiency ulcers, wounds resulting from cosmetic treatments, wounds resulting from ablative laser skin treatments, wounds resulting from chemical peels, wounds resulting from dermabrasion, wounds resulting from adverse drug reactions, wounds resulting from toxic epidermal necrosis, wounds resulting from Leigh syndrome, wounds resulting from Stevens-Johnson syndrome, and wounds resulting from radiation dermatitis.
[0115] 65. A method of treating a patient's wound, the method comprising applying a lotion as described in any one of embodiments 43-51 topically to at least a portion of the wound.
[0116] 66. The emulsion as described in any one of embodiments 43-51, for use in a method of treating a wound.
[0117] 67. The method or emulsion for use as described in embodiment 66, wherein the wound is selected from the group consisting of: burns, surgical skin damage, superficial injuries, chronic wounds, pressure sores, diabetic foot ulcers, chronic venous ulcers, arterial insufficiency ulcers, wounds resulting from cosmetic treatments, wounds resulting from ablative laser skin treatments, wounds resulting from chemical peels, wounds resulting from dermabrasion, wounds resulting from adverse drug reactions, wounds resulting from toxic epidermal necrosis, wounds resulting from Leigh syndrome, wounds resulting from Stevens-Johnson syndrome, and wounds resulting from radiation dermatitis.
[0118] 68. A method of treating a patient's wound, the method comprising applying a foam, as described in any one of embodiments 52-60, topically to at least a portion of the wound.
[0119] 69. The foam as described in any one of embodiments 52-60, for use in a method of treating a wound.
[0120] 70. The method or foam for use as described in embodiment 69, wherein the wound is selected from the group consisting of: burns, surgical skin damage, superficial injuries, chronic wounds, pressure sores, diabetic foot ulcers, chronic venous ulcers, arterial insufficiency ulcers, wounds from cosmetic treatments, wounds from ablative laser skin treatments, wounds from chemical peels, wounds from dermabrasion, wounds resulting from adverse drug reactions, wounds resulting from toxic epidermal necrosis, wounds resulting from Leigh syndrome, wounds resulting from Stevens-Johnson syndrome, and wounds resulting from radiation dermatitis.
[0121] 71. A method for treating bullous epidermolysis in a patient in need, the method comprising applying topically to the area of bullous epidermolysis in the patient an oleogel as described in any one of embodiments 13-31.
[0122] 72. The oleogel as described in any one of embodiments 13-31, for use in a method of treating epidermolysis bullosa.
[0123] 73. A method for treating bullous epidermolysis in a patient in need, the method comprising applying topically to the area of bullous epidermolysis in the patient as described in any one of embodiments 43-51.
[0124] 74. The emulsion as described in any one of embodiments 43-51, for use in a method of treating bullous epidermolysis.
[0125] 75. A method for treating bullous epidermolysis in a patient in need, the method comprising applying topically to the area of bullous epidermolysis in the patient as described in any one of embodiments 52-60.
[0126] 76. The foam as described in any one of embodiments 52-60, for use in a method of treating bullous epidermolysis. Attached Figure Description
[0127] Figure 1 The HPLC chromatograms of the extract from solid birch bark are shown at 210 nm (top) and 320 nm (bottom). Figure 1 The x-axis represents retention time (minutes), and the y-axis represents peak intensity (mAU).
[0128] Figure 2 The illustration shows the continuous extraction of birch bark to provide an extract containing betulin and one or more triterpenes. Detailed Implementation
[0129] definition
[0130] While it is believed that those skilled in the art will readily understand the following terms, the definitions are set forth in order to facilitate the explanation of the subject matter currently disclosed.
[0131] It should be understood that the terminology used herein is for the purpose of describing specific implementations only and is not intended to be restrictive.
[0132] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. Preferred methods, apparatus, and materials are described; however, any methods and materials similar to or equivalent to those described herein may be used in practice or testing of this disclosure. All references cited herein (including U.S. Patent Nos. 9,352,041, 8,828,444, 8,536,380, and 7,482,383) are incorporated herein by reference in their entirety for all purposes.
[0133] Following long-standing patent law practice, the terms “a,” “an,” and “the” when used in this application, including the claims, refer to “one or more.” Thus, for example, a reference to “carrier” includes one or more carriers, a mixture of two or more carriers, etc.
[0134] Unless otherwise indicated, all figures used in the specification and claims to represent amounts of components, reaction conditions, etc., shall be understood to be modified by the term “about” in all cases. Therefore, unless indicated to the contrary, the numerical parameters set forth in this specification and the appended claims are approximate values that may vary depending on the desired characteristics to be obtained by this application. Generally, the term “about” as used herein, when referring to measurable values such as weight, time, dosage, etc., means, depending on the specified amount, a variation of ±15% or ±10% in one instance, ±5% in another, ±1% in yet another, and ±0.1% in yet another, because such variations are suitable for performing the disclosed method.
[0135] "Administration" includes any method of administration, such as oral, subcutaneous, sublingual, transmucosal, parenteral, intravenous, intra-arterial, sublingual, topical, vaginal, rectal, ocular, otoscopic, nasal, inhalation, and transdermal. "Administration" may also include prescribing or completing a prescription for a dosage form containing a specific compound. "Administration" may also include providing instructions on methods involving a specific compound or a dosage form containing that compound.
[0136] As used herein, the verb "comprising" and its variations, as used in this specification and in the claims, are used in their non-limiting sense to mean including the item immediately following the word, but not excluding items not specifically mentioned.
[0137] The term "birch bark" refers to the bark of the white-barked birch tree. Preferred embodiments include birch bark derived from *Betula hainanensis* and *Betula pubescens*, as well as hybrids of the two species.
[0138] The term "relative retention time" (or "RRT") refers to the ratio of the retention time of an unknown peak to the retention time of the betulinol peak, and is calculated using the following formula:
[0139] RRT = RT 未知 / RT 白桦脂醇
[0140] RT 未知 It is the retention time of the unknown peak and RT 白桦脂醇 The retention time of betulinol peak (210 nm) was measured by the following HPLC method:
[0141]
[0142] Column: Phenomenex Kinetix C18, 2.6 μm, 150 x 2.1 mm.
[0143] As used herein, the term "substantially similar" means an analytical spectrum, such as an HPLC chromatogram or NMR spectrum, that is substantially similar to a reference spectrum in terms of peak position and intensity. For example, an HPLC chromatogram is considered "substantially similar" to a reference chromatogram if the peak position (relative retention time) in the HPLC chromatogram differs from that in the reference chromatogram by no more than ±5%. In some embodiments, the relative peak intensity in the HPLC chromatogram may differ from that in the reference chromatogram by no more than ±10%.
[0144] A "therapeutic effective amount" refers to the amount of an active substance that, when administered to a subject for the treatment of a disease, symptom, or other undesirable medical condition, is sufficient to produce a beneficial effect on that disease, symptom, or condition. Therapeutic effective amounts will vary depending on the chemical nature and formulation of the active substance, the disease or condition and its severity, and the age, weight, and other relevant characteristics of the patient to be treated. Determining a therapeutic effective amount of a given active substance is within the scope of those skilled in the art and typically requires only routine experiments.
[0145] The term "substantially free" means that the indicated ingredient is absent or present in only negligible amounts. In one embodiment, "substantially free" means less than about 10% (e.g., less than about 10% by weight). In other embodiments, "substantially free" means less than about 5% (e.g., less than about 5% by weight), less than about 2% (e.g., less than about 2% by weight), or less than about 1% (e.g., less than about 1% by weight) or about 0% (e.g., about 0% by weight). For example, an emulsion that is substantially free of emulsifiers will not contain significant amounts of any emulsifiers (e.g., less than about 10% by weight, less than about 5% by weight, less than about 2% by weight, or less than about 1% by weight; or 0% by weight). Similarly, an oleogel that is substantially free of solid birch bark extract particles larger than about 50 μm will not contain a significant amount of any solid birch bark extract particles larger than about 50 μm (e.g., containing less than about 10% by weight, less than about 5% by weight, less than about 2% by weight, or less than about 1% by weight of solid birch bark extract particles larger than about 50 μm; or containing 0% by weight of solid birch bark extract particles larger than about 50 μm).
[0146] Solid birch bark extract
[0147] This disclosure provides a solid birch bark extract that can be formulated in a clinically advantageous oleogel. Without being bound by any theory, it is believed that the chemical composition and particulate morphology of the solid birch bark extract produced according to the method of this disclosure are the cause of these advantages.
[0148] The solid birch bark extract disclosed herein can be characterized based on its chemical composition. In some embodiments, the solid birch bark extract of this disclosure comprises lupene and oleanane triterpenes. In particular, the birch bark extract may contain lupene triterpenes: betulinol, lupeol, and betulinic acid, and oleanane triterpenes: coca diol and oleanolic acid.
[0149] The presence of specific triterpenes in birch bark extracts can be determined using relative retention times obtained from HPLC chromatographic analysis. The following HPLC methods were used to determine the chemical composition of the solid birch bark extract of this disclosure:
[0150]
[0151] Column: Phenomenex Kinetix C18, 2.6 μm, 150 x 2.1 mm.
[0152] The Phenomenex Kinetix C18 column exemplifies an HPLC column with a C-18 modified silica stationary phase on a core-shell silica support (2.6 µm HILIC 100 Å) having the column dimensions described above.
[0153] When the solid birch bark extract was subjected to the HPLC chromatographic analysis method mentioned above, the relative retention time of betulinic acid was about 0.75-0.90, the relative retention time of oleanolic acid was about 0.84-0.97, the relative retention time of betulinol was 1.00, the relative retention time of gicosyl glycol was about 1.25-1.40, and the relative retention time of lupeol was about 3.50-4.15.
[0154] In some embodiments, the solid birch bark extract has the same properties as... Figure 1 The HPLC chromatograms are essentially the same.
[0155] In some embodiments, the solid birch bark extract comprises at least about 50% by weight, at least about 55% by weight, at least about 60% by weight, at least about 65% by weight, at least about 70% by weight, at least about 75% by weight, at least about 80% by weight, at least about 85% by weight, or at least about 90% by weight betulinic acid and one or more triterpenes. In some embodiments, the one or more triterpenes are selected from the group consisting of betulinic acid, oleanolic acid, coca glycol, and lupeol.
[0156] In some embodiments, the solid birch bark extract comprises at least one of the following substances: 3-β-phenanthroyl betulinol, acetate of methyl betulinic acid, acetyl oleanolic acid, allobenzyl betulinol, betulinaldehyde, betulinic acid, betulinone aldehyde, lupene-3β,20,28-triol, lupene-3β,20-diol (monogynol), oleanolic acid, sitosterol, ursolic acid, or β-amyrinol.
[0157] The solid birch bark extract disclosed herein can be characterized by the particle size of the solid birch bark extract particles. In some embodiments, the average particle size of the solid birch bark extract particles is less than about 100 μm, less than about 90 μm, less than about 80 μm, less than about 70 μm, less than about 60 μm, less than about 50 μm, less than about 40 μm, less than about 30 μm, or less than about 25 μm.
[0158] In other embodiments, the solid birch bark extract of this disclosure is substantially free of solid birch bark extract particles with a particle size greater than about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, about 90 μm, or about 100 μm.
[0159] In a preferred embodiment, the solid birch bark extract is derived from *Betula hyacinthus* and *Betula pubescens*, as well as hybrids of the two species.
[0160] Manufacturing process of solid birch bark extract
[0161] This disclosure provides a method for preparing a solid birch bark extract that can be formulated in a clinically advantageous oleogel. Typically, these methods include the following steps: obtaining a birch tree; peeling and processing the bark from the birch tree; contacting the processed birch bark with a suitable solvent to provide an extract containing betulinol and one or more triterpenes; and separating the birch bark extract containing betulinol and one or more triterpenes from the extract and drying it. In some embodiments, the separated birch bark extract is in solid form.
[0162] In some embodiments, the method includes: (a) contacting birch bark with a pharmaceutically acceptable solvent to form an extract comprising betulin and one or more triterpenes; (b) separating the birch bark from the extract; (c) cooling the extract, thereby crystallizing a portion of the betulin and one or more triterpenes from the cooled extract; (d) separating the crystallized betulin and one or more triterpenes from the cooled extract; and (e) drying the separated crystallized betulin and one or more triterpenes to provide the solid birch bark extract.
[0163] In some embodiments, the birch bark used in step (a) is first processed to improve the efficiency of extracting betulin and one or more triterpenes from the birch bark. For example, experiments have shown that the yield of the dry extract from the birch bark is highest when the extracted birch bark particles are small. In some embodiments, a grinder or other suitable equipment is used prior to step (a) to reduce the particle size of the birch bark until the resulting birch bark passes through a sieve with an aperture size of about 1.25 mm.
[0164] In some embodiments, the birch bark is contacted with a pharmaceutically acceptable solvent at a temperature between about 50°C and about 200°C. In other embodiments, the temperature is between about 60°C and about 100°C, between about 60°C and about 110°C, between about 60°C and about 120°C, between about 60°C and about 130°C, between about 70°C and about 130°C, between about 80°C and about 130°C, between about 90°C and about 130°C, or between about 100°C and 150°C. In some further embodiments, the temperature is between about 115°C and 130°C.
[0165] In some embodiments, the birch bark is contacted with a pharmaceutically acceptable solvent at a pressure between about 2 bar and 10 bar. In one embodiment, the pressure is about 4.5 bar.
[0166] Pharmaceutically acceptable solvents are known to those skilled in the art and include hydrocarbons, alcohols, ketones, ethers, sulfoxides, etc. Examples of pharmaceutically acceptable solvents include, but are not limited to, 1-butanol, 1-pentanol, 1-propanol, 2-butanol, 2-methyl-1-propanol, 2-propanol, 3-methyl-1-butanol, acetic acid, acetone, anisole, butyl acetate, dimethyl sulfoxide, ethanol, ethyl acetate, diethyl ether, ethyl formate, formic acid, heptane, hexane, isobutyl acetate, isopropyl acetate, methyl acetate, methyl ethyl ketone, methyl isobutyl ketone, pentane, propyl acetate, tert-butyl methyl ether, diisopropyl ether, methyl tert-butyl ether, methyl isopropyl ketone, and methyltetrahydrofuran.
[0167] In some embodiments, two or more pharmaceutically acceptable solvents are mixed to provide the pharmaceutically acceptable solvent.
[0168] In some embodiments, the birch bark is contacted with n-heptane at a temperature between about 60°C and 130°C for 8 to 12 minutes.
[0169] In some implementations, a continuous extraction process is used (shown in...). Figure 2 The following steps are performed: (a) contacting birch bark with a pharmaceutically acceptable solvent to form an extract containing betulin and one or more triterpenes, and (b) separating the birch bark from the extract.
[0170] In one embodiment of the continuous extraction process, birch bark is mixed with n-heptane at a ratio of approximately 1:14 to 1:16 (w / v). The mixture is continuously extracted using n-heptane as the extraction solvent at a temperature of approximately 115-130°C and a pressure of approximately 4.5 bar (nitrogen). The extracted cork is washed off at the lower end of the settling vessel with cold n-heptane, and the extract (a hot solution of triterpenes in n-heptane) is filtered (using a 10 µm filter) and then conveyed to the crystallization step through a second filter (using a 1 µm filter) at the upper end of the settling vessel.
[0171] In some embodiments, the cooling in step (c) is performed at temperatures ranging from about -20°C to about 35°C, from about -15°C to about 35°C, from -10°C to about 35°C, from about -5°C to about 35°C, or from about 0°C to about 35°C. In other embodiments, the extract cooled in step (c) is supersaturated by at least about 1, about 2, about 3, about 4, about 5, or about 6 times. In a preferred embodiment, the extract cooled in step (c) is supersaturated by about 2 or about 5 times.
[0172] In some embodiments, the drying step (e) is carried out under vacuum at a temperature of at least 50°C, at least 60°C, at least 70°C, at least 80°C, or at least 85°C. In some embodiments, the drying step (e) is carried out at a temperature of about 65°C to about 75°C, about 70°C to about 80°C, about 75°C to about 85°C, or about 85°C to about 95°C.
[0173] In some embodiments, the drying step (e) is carried out under vacuum at pressures less than about 90 mbar, less than about 80 mbar, less than about 70 mbar, less than about 60 mbar, or less than about 50 mbar. In some embodiments, the drying step (e) reduces the amount of pharmaceutically acceptable solvent in the dried birch bark extract to less than about 0.5% (w / w).
[0174] The present invention also provides a solid birch bark extract prepared according to the process described above.
[0175] Compositions containing solid birch bark extract
[0176] This disclosure provides clinically advantageous wound healing formulations comprising solid birch bark extract. These compositions comprise oleogels, emulsions, foams, and oleogel-impregnated sterile wound dressings. These compositions can be used as topical wound healing agents.
[0177] A gel is a finely dispersed system comprising a liquid phase and a solid phase. The solid phase forms a coherent three-dimensional framework and the two phases are interpenetrating. Olegels are hydrophobic gels based on nonpolar liquids (e.g., oils, waxes, or paraffins) with added gel-forming agents to achieve desired physical properties.
[0178] This disclosure provides oleogels comprising a nonpolar liquid and an oleogel-forming agent. Suitable nonpolar liquids for use in the oleogels of this disclosure include, for example, vegetable oils, animal or synthetic oils, waxes, and paraffins. In some embodiments, the nonpolar liquid is a vegetable oil selected from the group consisting of castor oil, peanut oil, jojoba oil, sunflower oil, olive oil, avocado oil, and almond oil. In a preferred embodiment, the nonpolar liquid is sunflower oil.
[0179] In some embodiments, the nonpolar liquid comprises at least one triglyceride. In some embodiments, the at least one triglyceride is Miglyol. In other embodiments, the nonpolar liquid comprises at least one C7 or higher hydrocarbon. In some embodiments, the at least one C7 or higher hydrocarbon is paraffin.
[0180] In some embodiments, the nonpolar liquid used in the oleogel has a peroxide value of less than about 15, less than about 10, less than about 5, less than about 4, less than about 3, or less than about 2. In some embodiments, the peroxide value of the nonpolar liquid does not exceed about 3. As used herein, the term "peroxide value" means that the peroxide value is determined according to European Pharmacopoeia 2.5.5.
[0181] This disclosure provides a method for preparing an oleogel. In some embodiments, after drying a solid birch bark extract, about 1% to about 20% by weight of the dried solid birch bark extract is dispersed in a nonpolar liquid to form an oleogel. In some embodiments, the nonpolar liquid is sunflower oil.
[0182] In some embodiments, the oleogel is sterile. The oleogel can be sterilized by suitable methods known to those skilled in the art, such as using ionizing radiation such as electron beams (EB), X-rays, or gamma rays. In some embodiments, the oleogel is sterilized with ionizing (e.g., gamma-ray) radiation at doses less than about 40 kGy, less than about 35 kGy, less than about 30 kGy, less than about 25 kGy, less than about 20 kGy, or less than about 15 kGy. In some embodiments, the oleogel is sterilized with ionizing (e.g., gamma-ray) radiation at doses ranging from about 5 to about 25 kGy, about 9 to about 25 kGy, about 10 to about 25 kGy, about 11 to about 25 kGy, about 12 to about 25 kGy, or from about 11 to about 20 kGy.
[0183] In some embodiments, the olegel comprises between about 1% and about 30% by weight of solid birch bark extract dispersed in about 70% to about 99% by weight of one or more nonpolar liquids, wherein the olegel contains at least one olegel-forming agent in addition to the solid birch bark extract particles. In some embodiments, the olegel comprises between about 1% and about 20% by weight of solid birch bark extract dispersed in about 80% to about 99% by weight of one or more nonpolar liquids, wherein the olegel contains at least one olegel-forming agent in addition to the solid birch bark extract particles.
[0184] In other embodiments, the olegel comprises between about 1% and about 30% by weight of solid birch bark extract particles dispersed in about 70% to about 99% by weight of one or more nonpolar liquids, wherein the dispersed solid birch bark extract particles are the sole olegel-forming agent in the olegel. In some embodiments, the olegel comprises between about 1% and about 20% by weight of solid birch bark extract dispersed in about 80% to about 99% by weight of one or more nonpolar liquids, wherein the olegel contains at least one olegel-forming agent in addition to the solid birch bark extract particles.
[0185] In some embodiments, the oleogel comprises: about 5% by weight of solid birch bark extract particles dispersed in about 95% by weight of one or more non-polar liquids; about 10% by weight of solid birch bark extract particles dispersed in about 90% by weight of one or more non-polar liquids; about 15% by weight of solid birch bark extract particles dispersed in about 85% by weight of one or more non-polar liquids; or about 20% by weight of solid birch bark extract particles dispersed in about 80% by weight of one or more non-polar liquids.
[0186] In the aforementioned embodiments, the amount of solid birch bark extract particles (e.g., about 1% by weight and about 20% by weight) comprises up to about 0.5% by weight of solid birch bark extract particles dissolved in a nonpolar liquid.
[0187] Centrifugation applied to the oleogel provides information about the tendency of the oleogel to separate (or segregate) nonpolar liquids. In some embodiments of the oleogel disclosed herein, after centrifugation at 25°C at 2750 g (e.g., 4400 rpm) for approximately 30 minutes, the segregation of nonpolar liquids from the oleogel is less than approximately 10%, approximately 9%, approximately 8%, approximately 7%, approximately 6%, approximately 5%, approximately 4%, approximately 3%, approximately 2%, approximately 1%, approximately 0.5%, or approximately 0.1%.
[0188] The oleogel of this disclosure can be characterized by its viscosity. In some embodiments, as measured using a cone-plate viscometer according to the rotational viscometer method described in European Pharmacopoeia 2.2.10, the viscosity of the oleogel at 200 / s ranges from about 0.5 Pa·s to about 4.0 Pa·s, and the thixotropic value of the oleogel ranges from about 200 Pa·s to about 1200 Pa·s.
[0189] The oleogel disclosed herein can also be characterized by its consistency value, as determined using a texture analyzer. Texture analysis is primarily concerned with measuring the mechanical properties of the product calculated from the results of two cycles of full texture analysis. This test is performed by applying controlled forces to the product and recording its response in the form of force, deformation, and time.
[0190] In this disclosure, consistency is the force [mN] required to penetrate 1 cm into a sample (e.g., oleogel) as measured using a material testing apparatus (texture analyzer) when penetrating an object (0.5 inch = 1.27 cm) in a cylindrical shape. The penetration velocity is 0.4 mm / s.
[0191] The oleogel of this disclosure can be distinguished from simple thickened mixtures of solid birch bark extract based on its consistency value. Specifically, the oleogel of this disclosure can be characterized by a consistency value of less than about 3000 mN and at least about 250 mN, as measured by a texture analyzer. In some embodiments, the consistency value of the oleogel is between about 300 and 2000 mN, as measured by a texture analyzer.
[0192] This disclosure also provides a method for preparing oleogels. In some embodiments, the method includes dispersing a solid birch bark extract in a suitable nonpolar liquid.
[0193] In some embodiments, a sterile wound dressing is provided comprising: a pad, and a therapeutic layer comprising an oleogel of the present disclosure. In some embodiments, the pad is an absorbent pad. In other embodiments, the pad is any solid material suitable for covering a wound, including cotton gauze. In some embodiments, the therapeutic layer of the oleogel is applied to one or more surfaces of the pad (e.g., surfaces of the pad intended for direct contact with a patient's skin or wound). In other embodiments, the pad is immersed in the oleogel such that the oleogel is disposed on at least a portion of the outer surface of the pad and optionally on at least a portion of the interior of the pad.
[0194] In some embodiments, the pad may contain a material suitable for wound healing that dissolves upon use to release an oleogel. Such materials may include absorbable materials containing collagen, alginate, etc.
[0195] The term emulsion refers to a heterogeneous system consisting of two liquids that are immiscible with each other or miscible to a limited extent, which is usually designated as a phase. In an emulsion, one of the two liquids is dispersed in the other liquid in the form of tiny droplets.
[0196] In some embodiments, an emulsion comprising a solid birch bark extract of the present disclosure is provided. Other embodiments provide an emulsion comprising an oleogel of the present disclosure.
[0197] In some embodiments, the emulsion of this disclosure contains an emulsifier. In some embodiments, the emulsifier is (hydropropyl)methylcellulose. In some other embodiments, the emulsion is substantially free of emulsifiers.
[0198] For treating skin wounds, foams may be superior to oleogels because foams can be applied to the wound with minimal contact, whereas oleogels require contact application. Foams are typically emulsion-based, in which the propellant is mixed with a dispersed lipid phase of the emulsion.
[0199] This disclosure provides a foam comprising an emulsion containing solid birch bark extract as described above.
[0200] In some embodiments, the foam comprises an oleogel consisting of about 5% to about 10% by weight of solid birch bark extract, and the emulsion is a water-in-oil emulsion consisting of the oleogel and about 20% to about 30% by weight of water.
[0201] In some other embodiments, the foam comprises an oleogel consisting of about 7% by weight of solid birch bark extract, and the emulsion is a water-in-oil emulsion consisting of the oleogel and about 25% by weight of water.
[0202] In some embodiments, the foam of this disclosure also comprises an emulsifier. Emulsifiers are known in the art as substances that stabilize emulsions and contain surfactants. Emulsifiers that can be used in this invention are those acceptable for pharmaceutical use, particularly for skin or wound contact. In some embodiments, suitable emulsifiers include emulsifying waxes, cetearyl alcohol, polysorbate 20, cetearyl alcohol polyether 20, etc. In some other embodiments, the emulsifier is selected from the group consisting of phosphatidylcholine, polyglycerol-3-methylglucose distearate, and combinations thereof.
[0203] In some embodiments, the oleogels, emulsions, and foams of this disclosure further comprise a disinfectant. In some other embodiments, the disinfectant is selected from the group consisting of ethanol, propan-1-ol (n-propanol), and propan-2-ol (isopropanol). In other embodiments, the oleogels, emulsions, and foams of this disclosure further comprise antibiotics, particularly lipophilic antibiotics, such as fluoroquinolones, macrolides, tigecycline, lincosamides, rifampin, linezolid, tetracycline, and chloramphenicol.
[0204] In some embodiments, the foams of this disclosure possess certain physical properties. In some embodiments, the foam index is greater than about 2. In other embodiments, using methods known in the art, the emulsion used in the foam exhibits an interfacial surface tension greater than about 4 nM / m. As used herein, the term "foam index" is the ratio of the foamed density to the unfoamed density of a specified material. For example, the foam index of a particular foam is the ratio of the density of the foamed material to the density of the material before foaming.
[0205] This disclosure also provides a pressurized container filled with the emulsion of the present invention and a pharmaceutically acceptable propellant, wherein the emulsion forms foam when at least a portion of the mixture is poured out of the container.
[0206] Method using solid birch bark extract
[0207] This disclosure also provides a method for treating a patient's wound by topically applying an effective amount of the disclosed oleogel, emulsion, or foam to at least a portion of the wound.
[0208] In some implementations, the wounds treated are selected from the group consisting of: burns (such as mild to severe burns), surgical skin lesions, superficial injuries, chronic wounds (such as pressure sores, diabetic foot ulcers, chronic venous ulcers, arterial insufficiency ulcers, etc.), cosmetic treatments (such as ablative laser skin treatments, chemical peels, dermabrasion, etc.), wounds resulting from adverse drug reactions (such as toxic epidermal necrosis, Lechner's syndrome, Stevens-Johnson syndrome, radiation-induced dermatitis, chemotherapy-induced dermatitis, etc.), rare skin diseases (such as epidermolysis bullosa, pemphigus vulgaris, bullous pemphigoid, bullous pemphigoid, foliaceous pemphigus, gangrenous pyoderma, etc.) and combinations thereof.
[0209] This disclosure also provides a method for treating bullous epidermolysis in patients in need, the method comprising applying an effective amount of the oil gel, emulsion or foam of this disclosure topically to the area of bullous epidermolysis in the patient.
[0210] By incorporating references
[0211] All references, articles, publications, patents, patent publications, and patent applications cited herein are incorporated in their entirety by reference for all purposes. However, any mention of any reference, article, publication, patent, patent publication, or patent application cited herein shall not and should not be construed as an affirmation or suggestion of any kind that they constitute valid prior art or form part of common general knowledge in any country of the world.
Claims
1. A solid birch bark extract comprising at least about 70% by weight betulin and one or more triterpenes selected from the group consisting of betulinic acid, oleanolic acid, coca glycol and lupeol.
2. The solid birch bark extract of claim 1, wherein when chromatographic analysis is performed according to the following HPLC method, the solid birch bark extract has a substantially identical HPLC chromatogram to that in Figure 1: Column: C18, 2.6 μm, 150 x 2.1 mm; Detector: 210 nm and 320 nm; The relative retention time of betulinic acid is about 0.75-0.90, the relative retention time of oleanolic acid is about 0.84-0.97, the relative retention time of betulinol is 1.00, the relative retention time of coca diol is about 1.25-1.40, and the relative retention time of lupeol is about 3.50-4.
15.
3. The solid birch bark extract as described in claim 1 or claim 2, prepared by a process comprising the following steps: (a) Contacting birch bark with a pharmaceutically acceptable solvent to form an extract containing betulin and one or more triterpenes; (b) Separating the birch bark from the extract; (c) Cool the extract, thereby crystallizing betulin and a portion of one or more triterpenes from the cooled extract; (d) Separate the crystallized betulinol and one or more triterpenes from the cooled extract; (e) The isolated crystalline betulinol and one or more triterpenes are dried to provide the solid birch bark extract; In step (e), approximately 1% to approximately 20% by weight of the dried solid birch bark extract dispersed in refined sunflower oil after drying forms an oil gel.
4. The solid birch bark extract as claimed in claim 3, wherein one or more of steps (a), (c), and (e) are performed under the following conditions: (i) The contact described in step (a) is performed at a temperature of about 60°C to about 130°C; (ii) Perform the cooling described in step (c) at a temperature of about -20°C to about 35°C; (iii) The drying described in step (e) is carried out at a pressure of less than about 70 mbar and a temperature of about 75°C to about 95°C.
5. The solid birch bark extract as claimed in claim 3, wherein two or more of steps (a), (c), and (e) are performed under the following conditions: (i) The contact described in step (a) is performed at a temperature of about 60°C to about 130°C; (ii) Perform the cooling described in step (c) at a temperature of about -20°C to about 35°C; (iii) The drying described in step (e) is carried out at a pressure of less than about 70 mbar and a temperature of about 75°C to about 95°C.
6. The solid birch bark extract as claimed in claim 3, wherein steps (a), (c), and (e) are performed under the following conditions: (i) The contact described in step (a) is performed at a temperature of about 60°C to about 130°C; (ii) Perform the cooling described in step (c) at a temperature of about -20°C to about 35°C; (iii) The drying described in step (e) is carried out at a pressure of less than about 70 mbar and a temperature of about 75°C to about 95°C.
7. The solid birch bark extract according to any one of claims 3-6, wherein the pharmaceutically acceptable solvent is a hydrocarbon or an alcohol or a combination thereof.
8. The solid birch bark extract according to any one of claims 3-7, wherein the pharmaceutically acceptable solvent is a hydrocarbon selected from the group consisting of n-pentane, n-hexane, or n-heptane.
9. The solid birch bark extract of claim 8, wherein the pharmaceutically acceptable solvent is n-heptane, and the contact is carried out at a temperature of about 60°C to about 130°C for about 8-12 minutes.
10. The solid birch bark extract according to any one of claims 3-9, wherein the cooled extract in step (c) is at least about 2 times supersaturated.
Citation Information
Patent Citations
Emulsion containing a plant extract, method for producing said emulsion and for obtaining said plant extract
US7482383B2
Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel
US8536380B2
Triterpene-containing oleogel-forming agent, triterpene-containing oleogel and method for producing a triterpene-containing oleogel
US8828444B2
Use of an oleogel containing triterpene for healing wounds
US9352041B2
